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Abstract
Background: The aim of this study was to develop and validate a reliable clinical prediction rule that could be employed to
identify patients at higher likelihood of mortality among those with hematological malignancies (HMs) and bacterial
bloodstream infections (BBSIs).
Methods and Findings: We conducted a retrospective cohort study in nine Italian hematological units. The derivation
cohort consisted of adult patients with BBSI and HMs admitted to the Catholic University Hospital (Rome) between January
2002 and December 2008. Survivors and nonsurvivors were compared to identify predictors of 30-day mortality. The
validation cohort consisted of patients hospitalized with BBSI and HMs who were admitted in 8 other Italian hematological
units between January 2009 and December 2010. The inclusion and exclusion criteria were identical for both cohorts, with
type and stage of HMs used as matching criteria. In the derivation set (247 episodes), the multivariate analysis yielded the
following significant mortality-related risk factors acute renal failure (Odds Ratio [OR] 6.44, Confidential Interval [CI], 2.36–
17.57, P,0.001); severe neutropenia (absolute neutrophil count ,100/mm3) (OR 4.38, CI, 2.04–9.43, P,0.001); nosocomial
infection (OR, 3.73, CI, 1.36–10.22, P = 0.01); age $65 years (OR, 3.42, CI, 1.49–7.80, P = 0.003); and Charlson Comorbidity
Index $4 (OR, 3.01, CI 1.36–6.65, P = 0.006). The variables unable to be evaluated at that time (for example, prolonged
neutropenia) were not included in the final logistic model. The equal-weight risk score model, which assigned 1 point to
each risk factor, yielded good-excellent discrimination in both cohorts, with areas under the receiver operating curve of 0.83
versus 0.93 (derivation versus validation) and good calibration (Hosmer-Lemshow P= 0.16 versus 0.75).
Conclusions: The risk index accurately identifies patients with HMs and BBSIs at high risk for mortality; a better initial
predictive approach may yield better therapeutic decisions for these patients, with an eventual reduction in mortality.
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Introduction
Intensified treatment protocols with chemotherapy and/or
hematological stem cell transplantation (HSCT) result in greater
chances of curing patients with hematological malignancies (HMs).
However, these potentially life-saving treatments increase the risk
of infectious complications. Bloodstream infections (BSIs) are
among the most common and severe complications observed in
patients with HMs, particularly if they are neutropenic, with a
prevalence ranging from 11 to 38% [1–6]. In addition, the onset of
BSIs within 5 days of stem cell infusion has been reported in
approximately 35% of patients who underwent HSCT [7].
Coagulase-negative staphylococci (CoNS), Staphylococcus aureus,
Enterobacteriaceae, and Pseudomonas aeruginosa have been reported, at
different frequencies, as the most prevalent organisms causing BSI
in patients with HMs [5,8–11].
The crude mortality rates for patients with BSI vary from 12%
to 42%, and attributable mortality rates as high up to 30% have
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been reported [1,3–5,7,9,11–13]. In addition, BSIs may lead to
delayed administration of chemotherapy, prolonged hospitaliza-
tion, and increased costs [5,14].
Several studies have evaluated the epidemiological and clinical
characteristics of bacterial BSI (BBSIs) in patients with HMs
[5,8,9,11]. However, some important uncertainties remain, and to
the best of our knowledge, no scoring system has yet been
developed that predicts the risk of mortality in patients with HMs
and concurrent BBSI.
The aim of the present study, conducted in 9 large Italian
hospitals, was to develop and validate a reliable, easy-to-use,
clinical prediction rule that could be employed to identify patients
with higher likelihood of mortality among those with HMs and
BBSI.
Materials and Methods
Ethics Statement
The institutional review board (Comitato Etico, Universita`
Cattolica del Sacro Cuore) approved the study, and informed
consent was waived because of the retrospecive observational
nature of the study.
Setting and Study Design
To identify risk factors for mortality in patients aged $18 years
with HMs and BBSI, we conducted a cohort study in nine Italian
hematological units. The derivation cohort consisted of patients
with BBSI and HMs admitted to the Catholic University Hospital,
located in Rome, between January 2002 and December 2008.
Recurrent episodes of BBSI for the same patient were excluded
from the study. The primary outcome measured was all-cause
mortality 30 days after BBSI onset. The survivor and nonsurvivor
subgroups were compared to identify predictors of 30-day
mortality.
The validation cohort consisted of individuals hospitalized with
BBSI and HMs who were admitted to 8 other Italian hematolog-
ical units between January 2009 and December 2010. The
inclusion and exclusion criteria were identical to those used for the
derivation cohort, and patients included in the validation cohort
were matched with those in the derivation set cohort according to
type and stage of HMs.
Definitions and Variables Analyzed
Data collected from hospital charts and the laboratory database
included patient demographics, disease and disease stage at time of
BBSI, type of HSCT (autologous or allogenic), medical history,
clinical/laboratory findings, treatment, and outcome of infection.
The following terms were defined before the data analysis.
A BBSI was defined as an infection manifested by (I) the
presence in at least 1 blood culture of bacteria other than skin
contaminants (i.e., diphtheroids, Bacillus spp., Propionibacterium spp.,
CoNS, micrococci) or (II) the presence of any bacterial species in
at least 2 consecutive blood cultures in a patient with a systemic
inflammatory response syndrome [15].
The date of the 1st positive blood culture (index culture) was
regarded as the date of BBSI onset.
Infections were classified as polymicrobial if 2 or more different
genera were recovered from specimens drawn during the first 48 h
of infection, regardless of whether the isolates came from the same
or different blood culture sets.
The BBSI was classified as nosocomial if the index blood culture
had been drawn more than 48 h after admission to our hospital
[16]. When the index culture had been drawn within the first 48 h
of hospitalization, the infection was classified as healthcare-
associated or community-acquired as defined by Friedman et al.
[17].
Neutropenia was defined as an absolute neutrophil count (ANC)
of ,500 cells/mm3. Neutropenia was considered prolonged if the
duration was $10 days and severe if the ANC was ,100 cells/
mm3.
Acute renal failure was defined as a serum creatinine value
.2 mg/dL in patients with previous normal renal function or an
increase of .50% of the baseline creatinine level in patients with
preexisting renal dysfunction.
The impact of comorbidities was determined by the Charlson
Comorbidity Index [18].
Statistical Analysis
Continuous variables were compared by Student’s t test for
normally distributed variables and by the Mann-Whitney U test
for non-normally distributed variables. Categorical variables were
evaluated with the x2 or two-tailed Fisher’s exact test. Odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated to
evaluate the strength of any association that emerged. Values are
expressed as the means 6 standard deviations (SD) (continuous
variables) or as percentages of the group from which they were
derived (categorical variables). Two-tailed tests were used to
determine statistical significance; a P value of ,0.05 was
considered significant.
Variables associated with mortality in the univariate analysis (P
#0.10) were included in a logistic regression model, and a
backward stepwise approach was used to identify independent
predictors of mortality; in addition, to develop a scoring system
that could be applicable at the onset of bacteremia, the variables
unable to be evaluated at that time (for example, prolonged
neutropenia) were not included in the final logistic model.
Variables were retained in the final model if the P value was #
0.05. The final regression model was transformed into a point-
based rule. An equal-weight risk score model, which assigned 1
point to each risk factor, was assessed; in addition, an unequal-
weight risk score model, with weighted scores assigned to each
variable obtained by dividing each regression coefficient by half of
the smallest coefficient and rounding to the nearest integer, was
also performed [19].
The discriminatory power of the prediction rule in the
derivation group was expressed as the area under the receiver-
operating characteristic curve (AUROC). An AUROC of 0.5
indicates no discriminative ability, and perfect discrimination (i.e.,
a test with 100% sensitivity and 100% specificity) is reflected by an
AUROC of 1. An AUROC exceeding 0.8 is usually indicative of
good to excellent prediction; those in the 0.7–0.8 and 0.6–0.7
ranges reflect moderate and low predictive power, respectively.
The sensitivity and specificity of the prediction rule - each with
95% CIs - were calculated at different cut-off values. Positive and
negative predictive values (PPV and NPV, respectively) were
obtained with standard methods.
All statistical analyses were performed using the Intercooled
Stata program, version 11, for Windows (Stata Corporation,
College Station, Texas, USA).
Results
Four hundred and ninety-four patients with HMs and BSI were
included in the study. Figure 1 indicates the distributions of
patients (both from the derivation and validation set) according to
the type and stage of HMs (matching criteria).
High Mortality Risk Patients with HMs and BBSI
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Derivation Cohort
Two hundred and fifty-one patients with HMs and BBSI met
the inclusion criteria for the derivation cohort. Four were excluded
because of missing data; thus, a total of 247 cases were included in
the analysis.
Table 1 summarizes the main clinical and demographic
characteristics of patients included in the derivation cohort.
The most common bacterial isolates were CoNS (28.1%), E. coli
(22.2%), P. aeruginosa (14.5%), and S. aureus (9.9%). The overall 30-
day mortality rate was 21.1% (52/247) (Table 1).
The univariate analysis revealed significant differences between
the survivor and nonsurvivor subgroups. A significantly higher
percentage of the nonsurvivor group were $65 years of age
(P = 0.007) and had nosocomial bacteremia (P = 0.003), indwelling
Figure 1. Distribution (%) of a) type of hematological malignancies and b) stages of disease in the derivation and validation sets.
AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; NHL, lymphoma; HD, Hodgkin’s disease; CML, chronic myeloid leukemia; MM, multiple
myeloma; CLL, chronic lymphocytic leukemia; BMT, bone marrow transplantation.
doi:10.1371/journal.pone.0051612.g001
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urinary catheter (P,0.001), chronic viral hepatitis (P = 0.03),
neutropenia (P = 0.02), prolonged neutropenia (P,0.001), severe
neutropenia (P,0.001), Charlson Comorbidity Index $4
(P,0.001), and a clinical presentation with acute renal failure
(P,0.001). Nonsurvivors were also more frequently treated with
corticosteroids (P,0.001); no significant differences between
survivors and nonsurvivors were observed in terms of the type of
etiological agents causing BBSI, although polymicrobial BBSI was
more frequent in nonsurvivors (P = 0.02).
In the logistic regression analysis, the five variables found to be
independently associated with 30-day mortality were the following:
acute renal failure (Odds Ratio [OR] 6.44, 95% confidence
interval [CI], 2.36–17.57); severe neutropenia (OR 4.38, 95% CI,
2.04–9.43); nosocomial infection (OR 3.73, 95% CI, 1.36–10.22);
age $65 years (OR 3.42, 95% CI, 1.49–7.80); and Charlson
Comorbidity Index $4 (OR 3.01, 95% CI, 1.36–6.65) (Table 2).
Table 1. Comparison of characteristics of case patients in the derivation and validation groups.
Variables No. (%) of patients
Derivation Set Validation Set
(n =247) (n =247)
Demographic information
Male sex 126 (51.0) 140 (56.7) 0.21
Age .65 years 60 (24.3) 47 (19.0) 0.16
Risk factors
Charlson Comorbidity Index .4 49 (19.8) 44 (17.8) 0.56
Chronic viral hepatitis 31 (12.6) 6 (2.4) ,0.001
Chronic renal failure 6 (2.4) 7 (2.8) 0.78
Diabetes mellitus 7 (2.8) 31 (12.6) ,0.001
Receipt of corticosteroidsa 105 (42.5) 81 (32.8) 0.02
Neutropenia 163 (65.9) 234 (94.7) ,0.001
Severe neutropenia (PMN ,100/mm3) 87 (35.2) 144 (58.3) ,0.001
Prolonged neutropenia ($10 days ) 99 (40.1) 166 (67.2) ,0.001
Presence of central venous catheter 114 (46.2) 215 (87.0) ,0.001
Presence of urinary catheter 49 (19.8) 29 (11.7) 0.01
Presence of nasogastric tube 6 (2.4) 2 (0.8) 0.15
Total parenteral nutritionb 4 (1.6) 73 (29.6) ,0.001
Etiological agents
Monomicrobial Gram-positive bacteremia 123 (55.7) 81 (38.4) ,0.001
Coagulase-negative Staphylococcus spp. 62 (28.1) 44 (20.8) 0.08
Staphylococcus aureus 22 (9.9) 7 (3.3) 0.005
Enterococcus spp. 15 (6.8) 7 (3.3) 0.10
Streptococcus spp. 11 (4.9) 12 (5.7) 0.74
Monomicrobial Gram-negative bacteremia 98 (44.3) 130 (61.6) ,0.001
Escherichia coli 49 (22.2) 73 (34.6) 0.004
Klebsiella pneumoniae 8 (3.6) 11 (5.2) 0.42
Pseudomonas aeruginosa 32 (14.5) 24 (11.4) 0.34
Enterobacter spp. 2 (0.9) 8 (3.8) 0.05
Polymicrobial bacteremia 26 (10.5) 36 (14.6) 0.17
Nosocomial bacteremia 178 (72.1) 190 (76.9) 0.22
Acute renal failure 25 (10.1) 20 (8.1) 0.43
30-day mortality 52 (21.1) 30 (12.1) 0.007
aDuring the 3 months preceding index blood culture.
bDuring the 30 days preceding index blood culture.
doi:10.1371/journal.pone.0051612.t001
Table 2.Multivariate logistic regression analysis of risk factors
for mortality in patients with bacteremia and hematological
malignancies.
Variables P value OR (95% CI)
Acute renal failure ,0.001 6.44 (2.36–17.57)
Severe neutropenia ,0.001 4.38 (2.04–9.43)
Nosocomial infection 0.01 3.73 (1.36–10.22)
Age $65 years 0.003 3.42 (1.49–7.80)
Charlson Comorbidity Index $4 0.006 3.01 (1.36–6.65)
doi:10.1371/journal.pone.0051612.t002
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Validation Cohort
Three hundred and forty-eight patients with HMs and BBSI
were observed in the 8 hospitals involved in the validation study,
and 247 were selected by matching criteria with patients from the
derivation set; these were included in the validation cohort. Their
baseline characteristics are summarized in Table 1. Compared to
the validation cohort, the derivation cohort contained a higher
percentage of patients with chronic viral hepatitis (P,0.001), who
had received corticosteroids (P = 0.02), and had indwelling urinary
catheter (P,0.001); on the contrary, compared to the derivation
cohort patients, patients included in the validation set had higher
rates of diabetes mellitus (P,0.001), neutropenia (P,0.001),
indwelling central venous catheter (CVC) (P,0.001), and total
parenteral nutrition (P,0.001). In terms of the etiological agents
causing BBSI, monomicrobial cases were caused more frequently
by Gram-positive bacteria in the derivation set (P,0.001) and by
Gram-negative bacteria in the validation set (P,0.001).
Construction and Validation of the Predictive Scoring
System
Derivation set. A scoring system that could be used to
predict mortality was developed based on the independent risk
factors that were identified in the multivariate analysis. An equal-
weight risk score model was assessed first, assigning 1 point to each
risk factor. The distributions of scores according to outcome and of
variables for different score points are reported in Tables 3 and 4,
respectively.
The AUROC for these data was 0.83 (95% CI, 0.78–0.89),
indicating that the model is an excellent predictor of mortality
(Figure 2). The results of Hosmer-Lemshow chi-squared testing
(P= 0.17) were indicative of good calibration. The prediction rules
derived using this scoring system are listed in Table 5 for different
thresholds, with the associated sensitivities, specificities, positive
and negative predictive values, and overall accuracy. Using a cut-
off score of 3 points to discriminate between high-risk and low-risk
patients, the scoring system was found to have a sensitivity of 58%,
a specificity of 90%, a positive predictive value of 61%, a negative
predictive value of 89%, and an overall accuracy of 83%. Patients
with scores of $3 points had an OR for mortality of 5.12 (95% CI
5.75–27.85, P,0.001).
The unequal-weight model, which assigned a different weight to
each risk factor based on the multivariable logistic regression
coefficient, had the same AUROC values and similar calibration
for both the cohorts; because the equal-weight risk score model
was easier to apply than the unequal model, we chose to report on
the first model only.
Validation set. The prediction rules derived from the scoring
system in the validation set are listed in Table 5 with the
prognostic performance parameters for the main cut-offs. The
ORs for mortality were even higher than those observed in the
derivation cohort: 78.46 (95% CI 23.50–293.09, P,0.001) for
scores .3. As shown Figure 2, when the prediction rule was
applied in the validation cohort, the model once again exhibited
excellent predictive power (AUROC 0.95; 95% CI, 0.89–1.00)
and good calibration (Hosmer-Lemshow P = 0.75).
Application of the model in the combined cohort. When
we combined the two cohorts (n = 494), the predictive effects of the
model were similar to those observed in the derivation and
validation sets. The ORs for mortality associated with a score of
$3 was 24.18 (95% CI 12.94–45.33, P,0.001). The 3 cut-off
displayed a sensitivity, specificity, PPV, NPV, and an overall
accuracy of 67%, 92%, 63%, 93%, and 88%, respectively. In the
combined cohort, the prediction rule had an AUROC of 0.86
(95% CI, 0.83–0.89) (Figure 2).
Discussion
A score that can be used to predict the likelihood of mortality is
useful in the evaluation of patients with severe infections because it
offers criteria to use when choosing a clinical management
strategy. In high-risk populations, such as those admitted to
intensive care units (ICUs), several scores are already widely used
to predict clinical outcomes [20–22]. However, published studies
incorporating analyses that establish a risk score for mortality in
patients with HMs are scarce and mostly based on adult or
pediatric patients in the setting of ICU admissions or on patients
who developed febrile neutropenia [23–26].
To the best of our knowledge, there have been no publications
to date reporting the analysis of mortality-based scores in adult
non-ICU patients affected by HMs with concurrent BBSI. We
have developed and validated an easy-to-use risk stratification tool
that is based on five variables that were found to be independently
associated with mortality in a population of 494 patients.
Our study was conducted in nine hematological centers that
regularly admit high numbers of patients with HMs. The possible
confounding effects of different types of HMs and/or various
stages of treatment were minimized by matching patients in the
derivation and validation cohorts according to these parameters.
The multivariate model identified five factors associated with a
higher mortality for patients with BBSI and HMs. These include
Table 3. Distribution of scores in the derivation and validation sets.
No. (%) of patients
Points Derivation Set Validation Set
Nonsurvivors Survivors Total Nonsurvivors Survivors Total
0 0 30 (100) 30 0 13 (100) 13
1 5 (5.1) 93 (94.9) 98 0 83 (100) 83
2 17 (24.3) 53 (75.7) 70 5 (4.4) 108 (95.6) 113
3 22 (61.1) 14 (38.9) 36 9 (47.4) 10 (52.6) 19
4 7 (58.3) 5 (41.7) 12 13 (81.3) 3 (18.7) 16
5 1 (100) 0 1 3 (100) 0 3
Total 52 (21.1) 195 (78.9) 247 30 (12.2) 217 (87.8) 247
doi:10.1371/journal.pone.0051612.t003
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acute renal failure, severe neutropenia (ANC ,100 cells/mm3),
nosocomial infection, age $65 years, and Charlson Comorbidity
Index $4.
Our score is simple to calculate and is constructed from
variables that are readily available at the time of admission and
can be generated from the demographic characteristics, elements
of the patient history, and routine clinical findings. This score
provided good discrimination of mortality risk in both the
derivation and validation sets, with AUROCs indicative of an
excellent predictive power. Furthermore, the fact that the patients
included in the validation cohort came from 8 different hospitals
and were hospitalized during different time periods increases the
likelihood that our findings can be generalized to a broad range of
patients with HMs.
The overall mortality rate was lower (12.1%) in the validation
cohort than in the derivation cohort (20.6%); this finding is
important considering the better global performance of this score
in the validation cohort. In addition, the prevalence of Gram-
negative agents, which are usually associated with a worse
outcome, is significantly higher in the validation cohort than in
the derivation cohort; this result reinforces the predictive value of
the score independent of the etiological agents responsible for the
BBSI.
When a threshold of $3 was used, the specificity of prediction
was over 90% in the derivation set and 94% in the validation set.
Table 4. Distribution of variables according to score points in the derivation and validation sets.
No. of patients Total
Points Population set Variables
Acute renal
failure
Severe
neutropenia
Nosocomial
infection Age $65 years
Charlson Comorbidity
Index $4
1 Derivation 0 10 72 13 3 98
Validation 0 7 59 14 3 83
2 Derivation 3 42 60 22 13 70
Validation 1 102 94 16 13 113
3 Derivation 13 24 33 16 22 36
Validation 3 17 18 3 16 19
4 Derivation 8 10 12 8 10 12
Validation 13 15 16 11 9 16
5 Derivation 1 1 1 1 1 1
Validation 3 3 3 3 3 3
doi:10.1371/journal.pone.0051612.t004
Figure 2. Receiver operator characteristic curves (ROC) for the scoring system in the derivation set, validation set, and combined
populations.
doi:10.1371/journal.pone.0051612.g002
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Although sensitivity was relatively low at 58% in the derivation set,
it reaches 83% in the validation set, and the high specificity of the
prediction could improve the targeting of patients with a higher
mortality risk.
Decisions related to the initiation of more intensive care
treatments are challenging, especially when they concern patients
with cancer. While the decision to admit patients with cancer to
ICUs is difficult to make and should be based on the prognosis for
each patient, the application of close patient monitoring and life-
support measures should be implemented in all patients with BBSI
and a high risk of mortality (i.e., $3 points with our score).
In the updated clinical practice guideline for the use of
antimicrobial therapy in neutropenic patients with cancer
developed by the Infectious Diseases Society of America (IDSA),
two different risk classifications have been proposed for identifying
high-risk patients: the first is based on expert opinion and identifies
high-risk patients as those with anticipated prolonged ($7 days
duration) and profound neutropenia (ANC ,100 cells/mm3
following cytotoxic chemotherapy) and/or significant medical co-
morbidities; the second classification risk proposed is the
Multinational Association for Supportive Care in Cancer
(MASCC) scoring system, with a cut-off #21 to identify high-
risk patients [27].
The MASCC scoring system, which had been validated only for
patients with febrile neutropenia and cancer, has been subse-
quently applied in a cohort of bacteremic patients with cancer,
confirming an approximate correlation between score and risk of
complications and death; however, no stratifications have been
made between patients with HMs and solid cancers (who could
have different characteristics, for example, regarding the role of
neutropenia in the development and outcome of BBSIs) [28]. In
addition, as highlighted in the updated IDSA guidelines [27], a
fundamental difficulty with the MASCC system is the lack of a
clear standardized definition of one of its major criteria, i.e., the
‘‘burden of febrile neutropenia’’ and symptoms associated with
that burden, which might complicate the uniform application of
the MASCC tool.
Our scoring system has been developed specifically for
hospitalized patients with HMs and concurrent BBSI, and it can
be applied soon after BBSI onset. For this reason, it could be used
for risk assessment in the setting of patients with HMs and BBSI,
as well as in association with the classifications proposed in the
IDSA guidelines for the management of patients with febrile
neutropenia and cancer.
Finally, inappropriate antimicrobial therapy during the empir-
ical phase of treatment has been well demonstrated as the main
risk factor for mortality in non-hematological patients with BBSI
[29,30], and the same finding has also been reported in patients
with HMs [12,13]. The use of the present scoring system could
provide useful information for prescribing a more broad spectrum
empirical therapy according to individual (i.e., previous coloniza-
tion and/or infections) and local bacterial epidemiology in patients
with scores $3, until microbiological data become available.
It is important to note that the application of the scoring system
in empirical treatment decision-making processes needs further
validation to quantify its value as a risk assessment tool compared
with the clinical judgment of hospitalists, which is likely to be
variable from one setting to another.
In conclusion, we stress that BBSI in patients with HMs is a
frequently observed clinical condition that requires prompt
recognition and treatment with adequate antibacterial therapy,
with consideration of the increasing number of multi-drug resistant
etiological agents. Our results have demonstrated that patients
with BBSI at higher levels of mortality risk can be reliably
identified by the application of a simple clinical prediction rule
based on five easy-to-define variables that are readily available at
the time of BBSI onset. This type of risk stratification could be an
important strategy for improving clinical decision-making in high-
risk patients, such as patients with HMs.
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Table 5. Model and risk score performance: derivation set (n = 247) and validation set (n = 247).
TP FP TN FN Se Sp PPV NPV Acc
Derivation set
Score $ 1 52 165 30 0 100 15 24 100 33
Score $ 2 47 72 123 5 90 63 39 96 69
Score $ 3 30 19 176 22 58 90 61 89 83
Score $ 4 8 5 190 44 15 97 62 81 80
Score = 5 1 0 195 51 2 100 100 79 79
Validation set
Score $ 1 30 204 13 0 100 6 13 100 17
Score $ 2 30 121 96 0 100 44 20 100 51
Score $ 3 25 13 204 5 83 94 66 98 93
Score $ 4 16 3 214 14 53 99 84 94 93
Score = 5 3 0 217 27 10 100 100 89 89
Abbreviations: TP, number of true positives; FP, number of false positives; FN, number of false negatives; TN, number of true negatives; Se, sensitivity; Sp, specificity;
PPV, positive predictive value; NPV, negative predictive value; Acc, rate of accuracy of the risk score model.
doi:10.1371/journal.pone.0051612.t005
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